Original from: 360dx

Foundation Medicine announced on Monday that it is expanding its partnership with Sequanta Technologies to provide its genomic profiling tests for research and oncology therapy development in China.

Foundation will conduct a technology transfer of its FoundationOne CDx and FoundationOne Liquid CDx tests for research and investigational uses. FoundationOne Liquid CDx will be transferred in November 2023 and FoundationOne CDx will be transferred in March 2024, Foundation noted in a statement. The genomic profiling tests use next-generation sequencing to analyze more than 300 cancer-related genes and have received approval from the US Food and Drug Administration for multiple companion diagnostic indications. 

Under the new deal, Sequanta will serve as a partner laboratory to Foundation and is responsible for performing the tests in China using the same parameters as all Foundation laboratories, including verification studies and concordance analysis, Foundation said.

The new agreement is an expansion of an existing partnership, as Roche subsidiary Foundation has served as Sequanta's in-house laboratory since 2014. 

The tech transfer "represents a major step forward in helping provide a unified global registration approach to biopharmaceutical companies to support their global trials in China," Foundation Chief Biopharma Business Officer Troy Schurr said in a statement.

Source: Foundation Medicine, Sequanta Expand Partnership to Use CDx for Therapy Development in China